Irla Carla de França Barbosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irla Carla de França Barbosa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Leila Bastos Leal
UFPE - Universidade Federal de Pernambuco
4 shared publications - Davi Pereira de Santana
Universidade Federal de Pernambuco
2 shared publications - Jeymesson Raphael Cardoso Vieira
Universidade Federal de Pernambuco
2 shared publications - Luzia Abilio da Silva
Department of Biochemistry, Biosciences Center, Federal University of Pernambuco (UFPE), Recife, Pernambuco, 50670-420, Brazil
2 shared publications - Cristiane Moutinho Lagos de Melo
Laboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, Brazil
1 shared publication - Cristiano Ferraz
Núcleo de Desenvolvimento Farmacêutico e Cosmético (NUDFAC), Universidade Federal de Pernambuco (UFPE), Recife, PE, Brasil
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-9
Segunda fase dos medicamentos genéricos no Brasil: implementação do estudo Vasoconstritor para corticoides tópicos dermatológicos
Introduction: In Brazil, the sale of generic medicines has been increasing, driven by the search for more affordable alternatives. However, this expansion necessitates the assurance of safety and efficacy, particularly in the case of topical medications containing corticosteroids. Until 2022, these products were exempt from bioequivalence testing, with only pharmaceutical equivalence being required. Objective: This study aimed to discuss the registration of topical medications containing corticosteroids in Brazil, highlighting recent regulatory changes and the impact of the mandatory implementation of the Vasoconstrictor Assay (VCA). Method: The methodology consisted of a systematic review of scientific literature and national and international regulatory guidelines, focusing on the registration criteria for topical corticosteroid medications. The study provided a detailed examination of the VCA, a pharmacodynamic test that evaluates the degree of skin blanching following drug application, divided into a pilot study (defining Emax and ED50) and a main study (comparison with the reference product). Results: It was demonstrated that the VCA is widely adopted in international regulatory contexts, such as by the U.S. Food and Drug Administration (FDA) since 1995. In Brazil, its introduction presents a technical challenge, as most bioequivalence centers require appropriate expertise and infrastructure. Nevertheless, studies indicate that the method has the potential to effectively demonstrate bioequivalence. Conclusions: The requirement of the VCA represents a regulatory milestone in Brazil, fostering greater technical rigor in the registration of topical corticosteroid medications. Its adoption is essential to ensure the quality, safety, and efficacy of these products for the population.
- 12 December 2025
- Published by Vigilancia Sanitaria em Debate: Sociedade, Ciencia y Tecnologia in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
- p. 1-9
Open AccessSegunda fase dos medicamentos genéricos no Brasil: implementação do estudo Vasoconstritor para corticoides tópicos dermatológicos
Introduction: In Brazil, the sale of generic medicines has been increasing, driven by the search for more affordable alternatives. However, this expansion necessitates the assurance of safety and efficacy, particularly in the case of topical medications containing corticosteroids. Until 2022, these products were exempt from bioequivalence testing, with only pharmaceutical equivalence being required. Objective: This study aimed to discuss the registration of topical medications containing corticosteroids in Brazil, highlighting recent regulatory changes and the impact of the mandatory implementation of the Vasoconstrictor Assay (VCA). Method: The methodology consisted of a systematic review of scientific literature and national and international regulatory guidelines, focusing on the registration criteria for topical corticosteroid medications. The study provided a detailed examination of the VCA, a pharmacodynamic test that evaluates the degree of skin blanching following drug application, divided into a pilot study (defining Emax and ED50) and a main study (comparison with the reference product). Results: It was demonstrated that the VCA is widely adopted in international regulatory contexts, such as by the U.S. Food and Drug Administration (FDA) since 1995. In Brazil, its introduction presents a technical challenge, as most bioequivalence centers require appropriate expertise and infrastructure. Nevertheless, studies indicate that the method has the potential to effectively demonstrate bioequivalence. Conclusions: The requirement of the VCA represents a regulatory milestone in Brazil, fostering greater technical rigor in the registration of topical corticosteroid medications. Its adoption is essential to ensure the quality, safety, and efficacy of these products for the population.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59, e20179
Association of Rhizophora mangle and ascorbic acid in hydrogels: Evaluation of cytotoxic and immunomodulatory effects
Polyphenolics from Rhizophora mangle (R. mangle) have shown wound healing and anti- inflammatory effects that may be potentiated by being associated with ascorbic acid, an important substance for collagen and elastin synthesis that plays a role in tissue repair. In our study, we aimed to formulate an association of R. mangle and ascorbic acid in hydrogels and evaluate the association’s cytotoxic and immunomodulatory effects. In a pre-formulation study, three gelling polymers (i.e.xanthan gum, poloxamer and hydroxyethyl cellulose) were tested. The selected polymer (i.e. xanthan gum) was used to evaluate cytotoxic and immunomodulatory effects using flow cytometry. Xanthan gum (1.5%) had a homogeneous appearance, an orange colour, a smooth surface, intense brightness and the typical odour, as well as non-Newtonian pseudoplastic behaviour. With a pH of 5.0-5.3 and a non-cytotoxic profile, xanthan gum induced the proliferation and activation of CD4 +, CD8+ and NK T lymphocytes and the production of IL- 2, IL-4, IL-10, IL-17 and TNF-α cytokines in stimulated splenocytes. The results suggest that the association of R. mangle and ascorbic acid in 1.5% xanthan gum hydrogel may be promising in preparations for wound-healing processes.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59, e20179
Open AccessAssociation of Rhizophora mangle and ascorbic acid in hydrogels: Evaluation of cytotoxic and immunomodulatory effects
Polyphenolics from Rhizophora mangle (R. mangle) have shown wound healing and anti- inflammatory effects that may be potentiated by being associated with ascorbic acid, an important substance for collagen and elastin synthesis that plays a role in tissue repair. In our study, we aimed to formulate an association of R. mangle and ascorbic acid in hydrogels and evaluate the association’s cytotoxic and immunomodulatory effects. In a pre-formulation study, three gelling polymers (i.e.xanthan gum, poloxamer and hydroxyethyl cellulose) were tested. The selected polymer (i.e. xanthan gum) was used to evaluate cytotoxic and immunomodulatory effects using flow cytometry. Xanthan gum (1.5%) had a homogeneous appearance, an orange colour, a smooth surface, intense brightness and the typical odour, as well as non-Newtonian pseudoplastic behaviour. With a pH of 5.0-5.3 and a non-cytotoxic profile, xanthan gum induced the proliferation and activation of CD4 +, CD8+ and NK T lymphocytes and the production of IL- 2, IL-4, IL-10, IL-17 and TNF-α cytokines in stimulated splenocytes. The results suggest that the association of R. mangle and ascorbic acid in 1.5% xanthan gum hydrogel may be promising in preparations for wound-healing processes.
- Open Access
- 24 December 2020
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 139 (1) , 81-87
Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review
BACKGROUND: The World Health Organization has declared that a pandemic situation exists in relation to the disease caused by the new coronavirus, COVID-19. So far, the absence of a vaccine against the new coronavirus has led people worldwide to seek various therapeutic alternatives, including use of cholecalciferol. DESIGN AND SETTING: Narrative review developed by a research group at a public university in Recife (PE), Brazil. METHODS: We searched the literature on the use of cholecalciferol for prevention or treatment of COVID-19, using the MEDLINE and LILACS databases, with the keywords “vitamin D”, “cholecalciferol”, “SARS-CoV-2”, “COVID-19” and “coronavirus”, from January 1, 2020, to June 10, 2020. Narrative reviews, cohort studies and ecological studies were selected. RESULTS: We retrieved 32 references, of which 8 were considered eligible for intensive review and critical analysis. These comprised five narrative reviews, two observational studies and one protocol proposal. Most of the studies selected reported positive effects from use of vitamin D for prevention or treatment of COVID-19. However, there was little quantitative data to assess the real impact of using this vitamin as an intervention against this disease. CONCLUSIONS: Current studies on vitamin D used for purposes other than bone health promotion cannot be taken as support to justify its use in a disease as recent as COVID-19. Studies of greater robustness, with higher levels of clinical evidence, need to be conducted. Rational use of this vitamin needs to be ensured, thereby minimizing the impacts on the patient and the public healthcare system.
- 24 December 2020
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 139 (1) , 81-87
Open AccessCritical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review
BACKGROUND: The World Health Organization has declared that a pandemic situation exists in relation to the disease caused by the new coronavirus, COVID-19. So far, the absence of a vaccine against the new coronavirus has led people worldwide to seek various therapeutic alternatives, including use of cholecalciferol. DESIGN AND SETTING: Narrative review developed by a research group at a public university in Recife (PE), Brazil. METHODS: We searched the literature on the use of cholecalciferol for prevention or treatment of COVID-19, using the MEDLINE and LILACS databases, with the keywords “vitamin D”, “cholecalciferol”, “SARS-CoV-2”, “COVID-19” and “coronavirus”, from January 1, 2020, to June 10, 2020. Narrative reviews, cohort studies and ecological studies were selected. RESULTS: We retrieved 32 references, of which 8 were considered eligible for intensive review and critical analysis. These comprised five narrative reviews, two observational studies and one protocol proposal. Most of the studies selected reported positive effects from use of vitamin D for prevention or treatment of COVID-19. However, there was little quantitative data to assess the real impact of using this vitamin as an intervention against this disease. CONCLUSIONS: Current studies on vitamin D used for purposes other than bone health promotion cannot be taken as support to justify its use in a disease as recent as COVID-19. Studies of greater robustness, with higher levels of clinical evidence, need to be conducted. Rational use of this vitamin needs to be ensured, thereby minimizing the impacts on the patient and the public healthcare system.